Cardinal Health

Cardinal Health reported fiscal Q1 revenue of $67.51 billion (+4% y/y) and adjusted EPS of $3.26, beating estimates and prompting management to raise full-year adjusted EPS guidance to $12.80–$13.00. The Pharmaceutical and Specialty Solutions segment outperformed, driven by strong demand for generics and specialty therapeutics and high-teens growth in specialty; management highlighted MSO expansion and potential M&A. The Other segment missed on revenue and profit, while Global Medical Products saw a profit decline; the company repurchased $500 million of stock and reiterated free cash flow targets of $3.5–$4.0 billion. » Mais em cnbc.com

Cardinal Health said fiscal 2027 growth should normalize after fiscal 2026’s unusually strong specialty growth, customer onboarding and acquisitions. Management highlighted double-digit earnings growth across all five operating segments in fiscal 2026 and said it will continue expanding specialty and at-home care through MSO platforms, bolt-on deals and diabetes-related acquisitions. The company is prioritizing automated small-parcel distribution for higher-value at-home products, plans three more automated distribution centers, and reported strong cash flow toward its $10 billion objective. » Mais em finance.yahoo.com

Cardinal Health closed fiscal 2026 well above plan: normalized earnings per share exceeded the original forecast by more than $2.00, and all five operating segments delivered double-digit earnings gains, led by a 25% increase in specialty pharmaceutical distribution. The company has achieved roughly 90% of its target of $10 billion in cumulative free cash flow and cites progress in specialty pharma, managed services, at‑home solutions and GMPD. For 2027 management expects growth at or above the level of long‑term plan targets, but at a normalized pace; pressure from commodities and tariffs remains a risk. The acquisition pipeline is active, with the purchase of AdaptHealth’s diabetes business named the most significant upcoming transaction. » Mais em de.investing.com

At the Morgan Stanley Healthcare Conference, Cardinal Health said it expects earnings per share to grow 13–15% in fiscal 2027 and plans $1 billion in share repurchases. Management emphasized broad execution of its strategy: pharmaceutical wholesale remains the core business, while specialty, BioPharma Solutions, home care, nuclear medicine and logistics are the growth drivers. Specialty growth is likely to slow compared with last year’s boom; tariffs and regulatory changes remain watchpoints that the company plans to address through price adjustments and contract structures. » Mais em de.investing.com

Cardinal Health reports strong results for fiscal year 2026, driven by double-digit growth in its specialty business, whose revenue topped $50 billion for the first time. For 2027 management expects adjusted earnings per share growth of 13–15% and plans at least $1 billion in share repurchases and around $700 million in investments. Supportive factors include theranostics/PET expansion, MSO acquisitions and cost discipline; risks stem from tariffs, a low-margin GMPD business and a normalization of demand after a strong first half of 2026. » Mais em de.investing.com